Hypertension is called the silent killer disease. Complications caused by hypertension such as stroke, blindness, and kidney failure. Indonesia ranks second with the most hypertensive sufferers in the Southeast Asia region. Yogyakarta Special Region (DIY) is the third highest province of hypertensive patients at the age of ≥ 18. Treatment of hypertension is carried out for a lifetime, because the goal of treating hypertension is to control the patient's blood pressure. Therefore, the patient's burden must be quite large. The purpose of this study was to find out the results of the Cost Effectiveness Analysis study of Amlodipine or Captopril in outpatient primary hypertension patients at the Seyegan Health Center. This study is a non-experimental observational study with a cohort study design. Data retrieval was done retrospectively with the Total Sampling data collection technique, so that a sample of 111 patient medical records was obtained. Data analysis using univariate, namely the average cost and effectiveness, also uses pharmacoeconomic analysis in the form of ACER or ICER values. The statistical test in this study used the Mann-Whitney test and the Independent Sample T test. The results showed that the average cost of Amlodipin 5 mg therapy was IDR 22,000 with an effectiveness of 60%, Amlodipine 10 mg for IDR 47,150 with the effectiveness of 43.75%, and Captopril 25 mg for IDR 12,700 with a effectiveness of 50%. The results of ACER Amlodipine 5 mg were Rp. 367, Amlodipine 10 mg Rp1,078, and Captopril 25 mg IDR 254. ICER calculations were carried out because alternative drugs (Captopril 25 mg) had lower costs and effectiveness compared to comparable drugs (Amlodipine 5 mg), ICER results were obtained at Rp930. Treatment of primary hypertension at the Puskesmas Seyegan, the use of antihypertensive Captoril 25 mg is absolutely more cost effective than antihypertensive Amlodipine 10 mg. ICER calculations were carried out on Amlodipine 5 mg with Captopril 25 mg, obtained ICER value of Rp930 for each 1% increase in effectiveness.